We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Joseph Shatzel

Joseph Shatzel MD

Assistant Professor of Hematology-Oncology and Biomedical Engineering, Oregon Health & Science University, Portland, Oregon

Dr. Shatzel specializes in caring for adults with bleeding and clotting disorders along with a host of other non-malignant hematologic disorders. His NIH-funded research program focuses on the translational development of novel molecular targets in coagulation, including factors XI and XII, thrombopoietin, and plasminogen. He serves as primary investigator and medical monitor for multiple NIH-funded early-stage clinical trials of novel anticoagulants. His areas of interests include mechanistic insights in contact activation and defining the clinical utility of inhibitors of FXI and FXII for the prevention of medical device-related thrombosis and morbidity in sepsis. He currently serves as the Co-Director of Clinical Research for the department of Biomedical Engineering at the Oregon Health & Science University, and assistant program director the adult hematology fellowship at the Knight Cancer Institute. He has a strong commitment to mentorship and actively mentors and supports multiple trainees.

Disclosures

Dr. Shatzel is supported by the National Heart, Lung, and Blood Institute and reports receiving consulting fees from Aronora Inc.

Recent Contributions to PracticeUpdate:

  1. Abelacimab for VTE Prevention